robert goeltz  cytomx therapeutics inc  zoominfocom   robert c goeltz ii  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors robert c goeltz ii check out list of companies and businesses related to robert c goeltz ii find out robert c goeltz ii address and contact details view other people related to robert c goeltz ii  coworkers colleagues companions etc address  oyster point blvd suite  south san francisco  ca companies related to robert c goeltz ii cikcompany namepositioncompany addresscytomx therapeutics incchief financial officer  oyster point blvd suite  south san francisco  robert c goeltz ii on the web persons related to robert c goeltz ii  cytomx therapeutics incnamepositioncityheeger alansanta barbaraheeger alansanta barbaracanaan ix lpdirector westportcanaan partners ix llcwestporthomcy charlessouth san franciscodeerfield capital lp et alnew yorkmanagement co ny deerfielddeerfield mgmt iii lpnew yorkdeerfield private design fund iii lpnew yorkdeerfield special situations fund lpnew yorkjones elainesouth san francisconeil exterdirector bostonpayne fletchersouth san franciscojames e flynn owner new yorkgluck fredericksanta barbaragluck fredericksanta barbaragluck fredericksanta barbaragluck fredericksouth san franciscogluck fredericksouth san franciscowilcox garysanta barbarawilcox garysanta barbarafrederick w gluckdirector robert c goeltz iichief financial officer south san franciscohadley harbor master investors cayman lp owner bostonhuh hoyoungsouth san franciscohuh hoyoungsouth san franciscohoyoung huhdirector san carlosrachel humphreychief medical officer san diegoelaine v jonesnew yorkwilliam michael kavanaughcso head resnonclin dev south san franciscocynthia j laddsenior vp and general counsel south san franciscomark j levincambridgesean a mccarthypresident and ceo south san franciscomarion mccourtdirector san franciscopfau michaelsanta barbarastagliano nancysanta barbarastagliano nancysanta barbaraexter neilsouth san franciscoexter neilsouth san franciscohumphrey rachelsouth san franciscodebanjan raychief financial officer south san franciscojohn a scarlettdirector south san franciscomccarthy seansouth san franciscomccarthy seansouth san franciscotimothy m shannondirector new havenkevin p starr owner cambridgerobert i tepper owner cambridgethird rock ventures gp lpbostonthird rock ventures lp owner bostonshannon timsouth san franciscotrv gp llcbostonmatthew p youngdirector dublin  compensation information for robert c goeltz ii chief financial officer and secretary of cytomx therapeutics inc  salarycom enterprise small business personal contact us log in salaries jobs education advice robert c goeltz ii executive compensation as chief financial officer and secretary at cytomx therapeutics inc robert c goeltz ii made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for robert c goeltz ii chief financial officer and secretary at cytomx therapeutics inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses cytomx therapeutics inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system cytomx therapeutics inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company rachel w humphrey md sean a mccarthy d phil w michael kavanaugh md robert c goeltz ii base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator stock screener  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballinsider transactionsdefault criteriainsider  restricted shareholder transactions of  resultsresults were generated a few mins ago pricing data is updated frequently currency in usdsymboldatesharesproceedstransaction detailsctmxautomatic sale at    per sharectmxoption execute at  per sharectmxoption execute at  per sharectmxacquisition non open market at  per sharectmxoption execute at    per sharectmxoption execute at    per sharethe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderthis game will teach youforge of empiressponsoredtrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insideryahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated goeltz ii robert c insider insider trades  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  individual insiders insider trades of goeltz ii robert c click on the column header to resort ascending ▲ or descending ▼ individual insider trades company relation last date ▼ type tran ownertype shares traded last price shares held cytomx therapeutics inc officer  form  automatic sell direct    cytomx therapeutics inc officer  form  acquisition non open market direct    highest rated articles of last week shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the mitel to acquire shoretel  quick facts miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated most rated stocks of last week rated stocks for nasdaq nyse and amex symbol  ratings consensus aapl  bullish of  ratings rate it fb  bullish of  ratings rate it tsla  bullish of  ratings rate it msft  bullish of  ratings rate it goog  bullish of  ratings rate it jpm  bullish of  ratings rate it gm  bullish of  ratings rate it bac  bullish of  ratings rate it nflx  bullish of  ratings rate it intc  bullish of  ratings rate it more most rated stocks closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robert c goeltz ii  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in robert c goeltz ii chief financial officer at cytomx therapeutics inc view full profile are you robert c goeltz ii claim your profile   sign up for equilar atlas and view robert c goeltz iis full profile with equilar atlas you can identify corporate executives in robert c goeltz iis network and community follow changes in robert c goeltz iis employment and moneyinmotion connect with robert c goeltz ii through your network of contacts robert c goeltz iis executive work history current chief financial officer cytomx therapeutics inc past to view robert c goeltz iis complete executive work history sign up now age      robert c goeltz iis biography mr goeltz joined us as chief financial officer in may  prior to joining us mr goeltz was chief financial officer of onyx pharmaceuticals inc after its acquisition by amgen inc in october  from august  to october  mr goeltz held leadership roles in business development commercial finance rd finance and corporate accounting at amgen inc mr goeltz was director of finance at tularik inc prior to its acquisition by amgen inc in august  he began his career working in the audit practice for ernst  young llp mr goeltz earned an mba from the ucla andersen school of management and a bba in business from  read more mr goeltz joined us as chief financial officer in may  prior to joining us mr goeltz was chief financial officer of onyx pharmaceuticals inc after its acquisition by amgen inc in october  from august  to october  mr goeltz held leadership roles in business development commercial finance rd finance and corporate accounting at amgen inc mr goeltz was director of finance at tularik inc prior to its acquisition by amgen inc in august  he began his career working in the audit practice for ernst  young llp mr goeltz earned an mba from the ucla andersen school of management and a bba in business from emory university he is also a certified public accountant inactive source cytomx therapeutics inc on    sign up for equilar atlas and view robert c goeltz iis full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like robert c goeltz ii more specifically youll be able to identify corporate executives in robert c goeltz iis network and community follow changes in robert c goeltz iis employment and moneyinmotion connect with robert c goeltz ii through your network of conections view full profile   search for over  executive profiles bio example robert c goeltz ii robert c goeltz iis connections  sign up now to view robert c goeltz iis  connections » william m kavanaugh chief scientific officer and head research and nonclinical development cytomx therapeutics inc matthew p young executive vice president and chief financial officer jazz pharmaceuticals public limited company elaine v jones former board member mirna therapeutics inc john a scarlett dir president and chief executive officer geron corporation timothy m shannon board member cytomx therapeutics inc rachel w humphrey chief medical officer cytomx therapeutics inc frederick w gluck board member cytomx therapeutics inc sean a mccarthy dir president and chief executive officer cytomx therapeutics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   ﻿ cytomx therapeutics inc ctmx scheduled to post quarterly earnings on tuesday  chaffey breeze daily ratings  news for cytomx therapeutics inc complete the form below to receive the latest headlines and analysts recommendationsfor cytomx therapeutics inc with our free daily email newsletter follow chaffeybreeze recent posts cytomx therapeutics inc ctmx scheduled to post quarterly earnings on tuesday ubs group ag has  position in yelp inc yelp walt disney company the nysedis position boosted by canada pension plan investment board tmobile us inc expected to post q  earnings of  per share tmus boyd gaming corporation nysebyd shares sold by ubs group ag dimensional fund advisors lp sells  shares of iridium communications inc irdm chipotle mexican grill inc nysecmg given “neutral” rating at wedbush dimensional fund advisors lp increases stake in alexion pharmaceuticals inc nasdaqalxn park hotels  resorts inc nysepk stock rating lowered by zacks investment research sunstone hotel investors inc sho to release quarterly earnings on tuesday jmp securities reiterates outperform rating for etrade financial corporation etfc q  eps estimates for lpl financial holdings inc nasdaqlpla increased by analyst thrivent financial for lutherans acquires  shares of expeditors international of washington inc nasdaqexpd simon property group inc nysespg to release quarterly earnings on tuesday ubs group ag buys  shares of liberty tripadvisor holdings inc ltrpa park city group inc nasdaqpcyg stake boosted by ubs group ag square inc sq to release quarterly earnings on tuesday q  eps estimates for willis towers watson public limited company nasdaqwltw lowered by analyst freightcar america inc rail downgraded by zacks investment research to “hold” sg americas securities llc lowers position in minerva neurosciences inc nasdaqnerv cytomx therapeutics inc ctmx scheduled to post quarterly earnings on tuesday posted by charlotte bryant on jul th   no comments cytomx therapeutics inc nasdaqctmx will be issuing its quarterly earnings data on tuesday august st analysts expect the company to announce earnings of  per share for the quarter cytomx therapeutics nasdaqctmx last announced its quarterly earnings data on friday may th the biotechnology company reported  earnings per share for the quarter beating the zacks’ consensus estimate of  by  cytomx therapeutics had a negative return on equity of  and a negative net margin of  the company had revenue of  million for the quarter compared to analyst estimates of  million on average analysts expect cytomx therapeutics to post  eps for the current fiscal year and  eps for the next fiscal year get cytomx therapeutics inc alerts shares of cytomx therapeutics inc nasdaqctmx opened at  on tuesday the stock’s market cap is  million the firm has a day moving average price of  and a day moving average price of  cytomx therapeutics inc has a one year low of  and a one year high of  several equities research analysts have commented on the stock jefferies group llc restated a “buy” rating and issued a  price target on shares of cytomx therapeutics in a research note on tuesday june th zacks investment research upgraded shares of cytomx therapeutics from a “hold” rating to a “buy” rating and set a  price target on the stock in a research note on wednesday may rd bidaskclub lowered shares of cytomx therapeutics from a “hold” rating to a “sell” rating in a research note on monday cowen and company restated a “buy” rating on shares of cytomx therapeutics in a research note on wednesday june th finally valuengine lowered shares of cytomx therapeutics from a “hold” rating to a “sell” rating in a research note on thursday may th three analysts have rated the stock with a sell rating three have assigned a hold rating and four have given a buy rating to the company the company has a consensus rating of “hold” and a consensus target price of  in related news major shareholder robert i tepper sold  shares of the firm’s stock in a transaction that occurred on thursday june th the shares were sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares in the company valued at  the transaction was disclosed in a document filed with the securities  exchange commission which is available through this hyperlink also insider sean a mccarthy sold  shares of the firm’s stock in a transaction that occurred on monday july rd the shares were sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares in the company valued at approximately  the disclosure for this sale can be found here insiders have sold  shares of company stock worth  in the last quarter company insiders own  of the company’s stock trademark violation warning “cytomx therapeutics inc ctmx scheduled to post quarterly earnings on tuesday” was first published by chaffey breeze and is owned by of chaffey breeze if you are accessing this piece of content on another website it was copied illegally and republished in violation of us  international trademark  copyright law the correct version of this piece of content can be accessed at httpswwwchaffeybreezecomcytomxtherapeuticsincctmxscheduledtopostquarterlyearningsontuesdayhtml about cytomx therapeutics cytomx therapeutics inc is a clinicalstage oncologyfocused biopharmaceutical company the company uses its probody technology platform to create cancer immunotherapies against clinically validated targets as well as to develop cancer therapeutics against difficulttodrug targets its pipeline is focused on the development of therapies in a set of modalities probody cancer immunotherapies probody drug conjugates tcell engaging probody bispecifics and procarnk cell therapies receive news  ratings for cytomx therapeutics inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for cytomx therapeutics inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website form  cytomx therapeutics for apr  filed by goeltz ii robert c research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  cytomx therapeutics for apr  filed by goeltz ii robert c by k wizard—  pm et  httparchivefastedgarcomavczchjgknzamzcz filed on april   more ctmx news cytomx therapeutics appoints marion mccourt to board of directors globenewswire   am et  cytomx therapeutics announces teleconference and webcast to provide corporate update globenewswire   pm et  cytomx announces fullyear  financial results globenewswire   pm et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  ctmx stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsctmx cytomx therapeutics inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all cytomx therapeutics to announce second quarter  financial results and provide midyear update globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer will announce financial results for the second quarter ended june   and provide a midyear update on august   after the nasdaq market closing briefcanaan ix lp dissolves passive stake in cytomx therapeutics as of june   sec filing reuters –  am et  cytomx therapeutics inc ctmx  canaan ix lp dissolves passive stake in cytomx therapeutics inc ctmx as of june   sec filing  canaan ix lp says had previously reported a passive stake of  percent as of december   source text further company coverage briefbvf partners lp reports  pct passive stake in cytomx therapeutics as of june   sec filing reuters –  am et  cytomx therapeutics inc ctmx  bvf partners lp reports  percent passive stake in cytomx therapeutics inc ctmx as of june   sec filing source text httpbitlytrugl further company coverage briefcytomx achieves development milestone in collaboration with abbvie reuters –  am et  cytomx therapeutics inc ctmx  cytomx achieves development milestone in strategic oncology collaboration with abbvie abbv for cdtargeting probody drug conjugate  cytomx therapeutics inc ctmx  will receive a  million milestone payment from abbvie abbv as part of  strategic oncology collaboration between companies source text for eikon further company coverage cytomx achieves development milestone in strategic oncology collaboration with abbvie for cdtargeting probody drug conjugate   globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced that the company has advanced cx a probody drug conjugate targeting cd and being developed in collaboration with abbvie into glp toxicology studies a key step on the path to filing an investigational new drug application in  cytomx announces the first patient treated in phase  proclaimcx trial globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced the treatment of the first patient in the proclaimcx study a phase  clinical trial evaluating cx as monotherapy in patients with select advanced solid tumors cytomx to present at the jefferies  global healthcare conference globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer will present at the jefferies  global healthcare conference a live audio webcast of the presentation will be available through the investors and news section of cytomxs website cytomx announces upcoming poster presentation at american society for clinical oncology annual meeting globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced an upcoming poster presentation for its lead product candidate cx a pdl targeting probody therapeutic for the treatment of cancer at the american society of clinical oncology annual meeting from june   in chicago illinois briefcytomx announces management team changes reuters –  pm et  cytomx therapeutics inc ctmx  cytomx announces management team changes  bob goeltz chief financial officer has decided to leave company to pursue new opportunities  cytomx therapeutics inc ctmx  cytomx is appointing debanjan ray as chief financial officer and head of corporate development effective immediately source text for eikon further company coverage cytomx announces management team changes globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced that bob goeltz chief financial officer has decided to leave the company to pursue new opportunities briefcytomx therapeutics qtrly loss per share   reuters –  am et  cytomx therapeutics inc ctmx  cytomx announces first quarter  financial results  q revenue  million versus  million cytomx announces first quarter  financial results globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today reported first quarter  financial results as of march   cytomx had cash cash equivalents and shortterm investments of  million cytomx therapeutics to announce first quarter  financial results globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer will announce financial results for the first quarter ended march   and provide an update on may   before the nasdaq market opening the company will not conduct a conference call in conjunction with this financial results press release cytomx therapeutics appoints marion mccourt to board of directors globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced the appointment of marion mccourt to its board of directors cytomx therapeutics announces teleconference and webcast to provide corporate update globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced that members of the management team will host a teleconference on monday march   at  am et to provide a corporate update cytomx announces fullyear  financial results globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today reported fullyear  financial results as of december   cytomx had cash and cash equivalents and shortterm investments of  million cytomx therapeutics to announce fullyear  financial results globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer plans to report fullyear  financial results on march   after the nasdaq market close the company will not conduct a conference call in conjunction with this financial results press release cytomx therapeutics to present at upcoming investor conferences globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced that sean mccarthy dphil president and chief executive officer will present at the th annual cowen and company healthcare conference on march   at  pm et cytomx to present at upcoming investor conferences globenewswire –  pm et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced that the companys management will participate in two upcoming investor conferences a live audio webcast for each event will be available through the investors and news section of cytomxs website cytomx announces the first patient treated in phase  proclaim trial globenewswire –  am et  cytomx therapeutics inc ctmx a biopharmaceutical company developing investigational probody therapeutics for the treatment of cancer today announced the treatment of the first patient in the proclaim cx study a phase  clinical trial evaluating cx a pdltargeting probody therapeutic as monotherapy and in combination with yervoy® or zelboraf® in patients with all types of cancers page page   next  todays and upcoming events aug  ctmx to announce q earnings after market confirmed aug  ctmx earnings conference call at  pm listen past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top msfg log in for events vcyt boot tbbk logm jack log in for events rev gifi rdwr impv find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map